Latest Breaking News On - Jay bradner - Page 1 : comparemela.com

Uplizna reduces IgG4 related disease flare risk by 87% in MITIGATE trial

The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.Topline results from the double-blind, randomized trial, called MITIGATE, demonstrated an 87% reduced risk for IgG4-related disease (IgG4-RD) flare in patients

Baystreet.ca - Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference

USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 .

USA News Group: Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More

Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More

Baystreet.ca - Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference